Questions from the Community: Examining the Application of Recent Research Advances into the Management of Patients with HR-Positive/HER2-Negative Metastatic Breast Cancer
Program Description
In the setting of advanced HR-positive/HER2-negative breast cancer (BC), the combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has become the standard of care as first-line therapy. Unfortunately, despite the profound benefits of this regimen, most if not all patients eventually develop progressive disease due to endocrine resistance. Fortunately, a wealth of targeted systemic treatment options (e.g., oral selective estrogen receptor degraders (SERDs), PI3K/AKT/mTOR pathway inhibitors) are becoming available to help overcome this inevitable resistance. However, with a variety of targets and indications of these agents and advancing data surrounding novel strategies, optimizing therapeutic selection is increasingly complex. Further, there is not yet clear guidance on how to effectively sequence these agents, particularly as novel strategies enter earlier-line settings and shift long accepted clinical paradigms.
To gain clinical pearls surrounding some of the most pertinent challenges affecting clinicians today, join Drs. Sarah Sammons, Komal Jhaveri, and Joyce O’ Shaughnessy as they answer and discuss real-world questions and cases submitted by community-based oncologists. Through this intervention, participants will have the opportunity to learn from the issues prioritized by their peers.
Target Audience
The target audience for this activity includes medical oncologists, oncology fellows, and advanced practice professionals (APPs) working in cancer care settings.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Appraise emerging data and ongoing research efforts addressing the evolving role of CDK4/6is to determine their optimal use in patients with de novo and previously treated HR-positive/HER2-negative advanced or metastatic BC
- Discuss biomarker testing approaches, including methodology and timing of testing/re-testing, in HR-positive/HER2-negative advanced BC to improve targeted treatment selection for patients with metastatic disease
- Describe published efficacy and safety data with systemic agents indicated or in development for ESR1-mutated, HR-positive/HER2-negative advanced or metastatic BC to optimally integrate these agents into clinical practice
- Assess the clinical efficacy and safety profiles of recently approved therapies targeting the AKT pathway—including PIK3CA, AKT1, and PTEN mutations—in patients with HR positive/HER2-negative mBC to customize therapeutic selection and improve long-term outcomes for these individuals
This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.
Accreditation Statement
This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Conflicts of Interest Disclosure Policy
- Advisory Board: AstraZeneca; Daichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Incyclix Bio, LLC; Novartis Pharmaceuticals Corporation; Pfizer; Seagen Inc.; Sermonix Pharmaceuticals
- Grants/Research Support: Daichi Sankyo, Inc.; Relay Therapeutics; Seagan Inc.; Sermonix Pharmaceuticals
- Consultant/Advisory Board: Novartis, Pfizer, AstraZeneca, Bristol Myers-Squibb, Genentech, AbbVie, Lilly, Blueprint Medicines, Seagen, Daiichi Sankyo, Biotheranostics, Sanofi, Gilead Sciences, Scorpion Therapeutics, Eisai, Bicycle Therapeutics, Taiho Pharmaceutical, Jounce Therapeutics, Intellisphere, Gilead Sciences
- Research Funding (paid to institution): Novartis, Genentech, Pfizer, Lilly, Zymeworks, Puma Biotechnology, Velosbio/Merck, AstraZeneca, Context Therapeutics, Scorpion Therapeutics, Blueprint Medicines, Gilead Sciences, Rayze Bio
- Consultant/Advisory Board: AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo, Inc.; DAVA Oncology; Eisai Inc.; Fishawack Health.; G1 Therapeutics, Inc.; Genentech, Inc.; Genzyme; GlaxoSmithKline; Gilead Sciences, Inc.; Lilly; Loxo Oncology; Merck & Co., Inc; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pierre Fabre Pharmaceuticals; Puma Biotechnology, Inc.; F. Hoffmann-La Roche Ltd; Samsung Bioepis; Sanofi; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Taiho Oncology, Inc.; Veru
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Commercial Support
Supported by an educational grant from AstraZeneca Pharmaceuticals and Genentech.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Attendance